These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 28253024)

  • 1. Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations.
    Koss CA; Bacchetti P; Hillier SL; Livant E; Horng H; Mgodi N; Mirembe BG; Gomez Feliciano K; Horn S; Liu AY; Glidden DV; Grant RM; Benet LZ; Louie A; van der Straten A; Chirenje ZM; Marrazzo JM; Gandhi M
    AIDS Res Hum Retroviruses; 2017 Aug; 33(8):778-783. PubMed ID: 28253024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study.
    Gandhi M; Glidden DV; Mayer K; Schechter M; Buchbinder S; Grinsztejn B; Hosek S; Casapia M; Guanira J; Bekker LG; Louie A; Horng H; Benet LZ; Liu A; Grant RM
    Lancet HIV; 2016 Nov; 3(11):e521-e528. PubMed ID: 27658870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals.
    Jotwani V; Scherzer R; Glidden DV; Mehrotra M; Defechereux P; Liu A; Gandhi M; Bennett M; Coca SG; Parikh CR; Grant RM; Shlipak MG
    J Acquir Immune Defic Syndr; 2018 Jun; 78(2):169-174. PubMed ID: 29767638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring.
    Gandhi M; Glidden DV; Liu A; Anderson PL; Horng H; Defechereux P; Guanira JV; Grinsztejn B; Chariyalertsak S; Bekker LG; Grant RM;
    J Infect Dis; 2015 Nov; 212(9):1402-6. PubMed ID: 25895984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishing adherence-concentration-efficacy thresholds of TDF-FTC pre-exposure prophylaxis for HIV prevention in African women: a protocol for the Women TDF-FTC Benchmark Study.
    Wu L; Saina M; Brown C; Chege D; Donnell D; Glidden DV; Ngure K; Mugo NR; Akelo N; Schaafsma T; Anderson PL; Mugwanya KK
    Front Reprod Health; 2024; 6():1325257. PubMed ID: 38860025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
    Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
    Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence.
    Celum C; Baeten JM
    Curr Opin Infect Dis; 2012 Feb; 25(1):51-7. PubMed ID: 22156901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
    Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
    Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis.
    Plosker GL
    Drugs; 2013 Mar; 73(3):279-91. PubMed ID: 23444256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.
    Hosek SG; Landovitz RJ; Kapogiannis B; Siberry GK; Rudy B; Rutledge B; Liu N; Harris DR; Mulligan K; Zimet G; Mayer KH; Anderson P; Kiser JJ; Lally M; Brothers J; Bojan K; Rooney J; Wilson CM
    JAMA Pediatr; 2017 Nov; 171(11):1063-1071. PubMed ID: 28873128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
    Mulligan K; Glidden DV; Anderson PL; Liu A; McMahan V; Gonzales P; Ramirez-Cardich ME; Namwongprom S; Chodacki P; de Mendonca LM; Wang F; Lama JR; Chariyalertsak S; Guanira JV; Buchbinder S; Bekker LG; Schechter M; Veloso VG; Grant RM;
    Clin Infect Dis; 2015 Aug; 61(4):572-80. PubMed ID: 25908682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis.
    Corneli AL; Deese J; Wang M; Taylor D; Ahmed K; Agot K; Lombaard J; Manongi R; Kapiga S; Kashuba A; Van Damme L;
    J Acquir Immune Defic Syndr; 2014 Jul; 66(3):324-31. PubMed ID: 25157647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
    Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG
    Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial.
    Mandala J; Nanda K; Wang M; De Baetselier I; Deese J; Lombaard J; Owino F; Malahleha M; Manongi R; Taylor D; Van Damme L
    BMC Pharmacol Toxicol; 2014 Dec; 15():77. PubMed ID: 25539648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results from a Pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender Women in the United States.
    Blumenthal J; Jain S; He F; Amico KR; Kofron R; Ellorin E; Stockman JK; Psaros C; Ntim GM; Chow K; Anderson PL; Haubrich R; Corado K; Moore DJ; Morris S; Landovitz RJ
    Clin Infect Dis; 2021 Oct; 73(7):1149-1156. PubMed ID: 33864370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
    Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM;
    Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kidney function and daily emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis against HIV: results from the real-life multicentric demonstrative project PrEP Brazil.
    Petruccelli KCS; Baía-da-Silva DC; Val F; Valões MS; Cubas-Vega N; Silva-Neto AV; Sampaio V; Alencar A; Pecoits-Filho R; Moreira RC; Cardoso SW; Moreira RI; Leite IC; Madruga JV; Kallas EG; Alencastro PR; Hoagland B; Grinsztejn B; Santos VGV; Lacerda MVG
    AIDS Res Ther; 2022 Feb; 19(1):12. PubMed ID: 35209929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California.
    Landovitz RJ; Beymer M; Kofron R; Amico KR; Psaros C; Bushman L; Anderson PL; Flynn R; Lee DP; Bolan RK; Jordan WC; Tseng CH; Dierst-Davies R; Rooney J; Wohl AR
    J Acquir Immune Defic Syndr; 2017 Dec; 76(5):501-511. PubMed ID: 28902074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
    Koenig HC; Mounzer K; Daughtridge GW; Sloan CE; Lalley-Chareczko L; Moorthy GS; Conyngham SC; Zuppa AF; Montaner LJ; Tebas P
    HIV Med; 2017 Jul; 18(6):412-418. PubMed ID: 28444867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study.
    Cressey TR; Siriprakaisil O; Klinbuayaem V; Quame-Amaglo J; Kubiak RW; Sukrakanchana PO; Than-In-At K; Baeten J; Sirirungsi W; Cressey R; Drain PK
    BMC Infect Dis; 2017 Jul; 17(1):496. PubMed ID: 28705153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.